A review concluded that lung toxicity including pneumonitis and interstitial lung disease occurred in 105 of 4943 patients (2.1%) [21] and other studies reported lung toxicity was 3.2% in patients treated with ALK-inhibitors [22]. This evidence concerns the gene ALK and pneumonitis.